Clinical trials: Flu
Influenza
Comparison of Full-dose Flu Vaccine to Half-dose Flu Vaccine
This study compared full-dose Flu vaccine to half-dose Flu-vaccine during the 2004-2005 flu season.
- Trial name
- NCT00283283
- Testing
- Fluzone® (Aventis Pasteur inactivated influenza vaccine)
- Where
- 2 sites in United States
- Volunteers
- 1,316 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Immunization, Healthy Volunteers
Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older
The purpose of this study is to assess the safety and immunogenicity of IIV-HD + NVXC19 vaccine compared to seasonal influenza vaccine (IIV-HD) and COVID-19 vaccine, adjuvanted (NVXC19) coadministered in adult participants 60…
- Conditions
- Immunization, Healthy Volunteers, COVID-19 Immunization, Influenza Immunization
- Trial name
- NCT07890454
- Testing
- IIV-HD (standalone), NVXC19 (EU licensed, standalone), IIV-HD + NVXC19 combination
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza, Myxovirus Infection
Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects
The present formulations are being developed for further study in the elderly population in order to generate additional supporting data.
- Trial name
- NCT00551031
- Testing
- Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1), Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 2), Split, Inactivated, Trivalent Influenza Vaccine (Standard dose)
- Where
- 29 sites in United States
- Volunteers
- 2,098 people, healthy volunteers welcome
- Sponsor
- Sanofi
Rheumatoid Arthritis
The Effect of Rituximab on the Humoral Response to Influenza Vaccine
Rituximab is a genetically engineered chimeric anti-CD20 monoclonal antibody that selectively targets CD20+ B cells and induces a transient depletion of the CD20+ mature B cell subpopulation.The objective of our study was to…
- Trial name
- NCT00466037
- Testing
- Influenza vaccine
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Healthy Volunteers, HIV Infection
Safety Study Comparing a Vaccine Transcutaneous Administration to the Intramuscular Route
The rationale for transcutaneous vaccination is based on the unique ability of cutaneous immune cells, especially Langerhans cells (LCs), to present antigens to the immune system.
- Trial name
- MANON-05 (NCT00261001)
- Testing
- Transcutaneous mode of administration, Intramuscular mode of administration
- Where
- 2 sites in Germany
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Objectif Recherche Vaccins SIDA
Influenza
Comparison of the Safety and Immune Response of Three Different Lots of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2004/2005
The objectives of the study are to assess the immunogenicity and safety among three different lots of the inactivated influenza vaccine (whole virion, Vero cell-derived) at Day 21 and Day 180 after vaccination.
- Trial name
- NCT00161811
- Testing
- Vero Cell-derived Influenza Vaccine, Egg cell-derived Influenza Vaccine
- Where
- 4 sites in Austria, Germany
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Safety Issues
Reactogenicity, Safety and Immunogenicity of an Universal Influenza Vaccine Uniflu
This is a single-site, randomized, double-blind, placebo-controlled study of Uniflu in fifty four (54) volunteers 18-60 years of age with a dose escalation.
- Trial name
- NCT03789539
- Testing
- LD Universal Influenza Vaccine Uniflu, HD Universal Influenza Vaccine Uniflu
- Where
- Russia
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- VA Pharma Limited Liability Company
HIV Infections
A Pilot Study of the Patterns of Cellular Gene Expression in HIV-1 Patients Following Clinical Events Which Increase Plasma Virus Concentrations
The factors that influence HIV disease progression are not well understood. While larger amounts of circulating virus (high 'viral loads') predict future adverse clinical events, many of the clinical factors responsible for high…
- Trial name
- NCT00001681
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Influenza
A Study of a Bivalent Influenza Peptide Conjugate Vaccine in Healthy Adults
This is a first in man study evaluating the tolerability and immunogenicity of BIPCV/IMX (V512) at increasing concentrations of influenza viral peptides A/M2+B/HA0 peptides and IMX, a saponin-based adjuvant.
- Trial name
- NCT00851266
- Testing
- V512
- Volunteers
- 187 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Influenza, Influenza Immunisation
H3N2 M2SR in Pediatric Population
This is a Phase I double-blind, randomized, placebo-controlled study in 50 healthy adolescents and children, 9-17 years of age, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT03553940
- Testing
- Influenza Virus Monovalent A/H3N2/Bris 10 M2SR Live Vaccine, Quadrivalent MDCK Inactivated Influenza Vaccine
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Human
Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults
The purpose of this study is to assess the safety and immunogenicity of different formulations of monovalent Influenza A/Astrakhan/3212/2020-like virus vaccine with AS03 adjuvant system in adults greater than or equal to (>=)18…
- Trial name
- NCT05975840
- Testing
- FLU Q-PAN H5N8 375_B, FLU Q-PAN H5N8 375_A, FLU Q-PAN H5N8 750_B
- Where
- 20 sites in United States
- Volunteers
- 518 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Orthomyxoviridae Infections
Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine
Following the licensure of sanofi pasteur's 90 µg rgA/Vietnam/1203/2004 pandemic influenza vaccine, efforts to develop a lower antigen dose formulation with improved immunogenicity using adjuvants were initiated.
- Trial name
- NCT00664417
- Testing
- Monovalent subvirion H5N1 influenza vaccine, Physiological saline
- Where
- 6 sites in United States
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- Sanofi
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Influenza
The Effects of Attenuated Versus Inactivated Flu Vaccine in Twin Sets
This is one project of a larger ongoing study related to the immune system's response to the flu virus. This study is designed to investigate the immune response to the live attenuated influenza vaccine (LAIV) vs.
- Trial name
- FLU-TW (NCT03898986)
- Testing
- Live attenuated influenza vaccine (LAIV4), Inactivated Influenza Vaccine (IIV4)
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Stanford University
Influenza B
Dose, Safety, and Pathogenicity of a New Influenza B Strain
This is an exploratory study of an influenza B challenge strain to determine the optimum infectious titer of challenge agent in healthy participants 18 to 55 years of age.
- Trial name
- NCT06254820
- Testing
- influenza B/Connecticut/1/21 virus part a dose arm 1, influenza B/Connecticut/1/21 virus part a dose arm 2, influenza B/Connecticut/1/21 virus part b dose 1
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hvivo
Influenza
Study of a Pandemic Influenza Vaccine in Elderly Participants
The World Health Organisation has warned that an influenza pandemic is inevitable. The avian influenza H5N1 virus strain is one of the leading candidates to cause the next influenza pandemic.
- Trial name
- NCT00376402
- Testing
- H5N1 Pandemic Influenza Vaccine
- Where
- 2 sites in Australia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Seqirus
Pregnancy Related, Influenza, Human
NK Cell Mediated Influenza Immunity During Pregnancy
Pregnant women have increased morbidity and mortality due to infection with influenza. Changes in T cell function have been proposed as possible mechanisms for this finding.
- Trial name
- Flu vaccine (NCT03196245)
- Testing
- There is no intervention.
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Stanford University
Influenza
Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years
This is a Phase Ib study in healthy adults (18-70 years) to evaluate the safety, tolerability, and immunogenicity of same season and sequential season vaccination schedules consisting of the 2012/2013 seasonal influenza DNA…
- Trial name
- NCT01676402
- Testing
- Seasonal Influenza DNA vaccine, TIV
- Where
- 4 sites in United States
- Volunteers
- 316 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza (Healthy Volunteers)
SAFE (Self-Administration of Flumist to ImprovE Uptake: A Household-Based Cluster Randomized Trial)
The flu is a health risk for Canadians. It causes up to 15,000 hospitalizations every year and is one of the top 10 causes of death. Getting a flu vaccine is the best way to prevent the flu and any severe complications.
- Trial name
- SAFE (NCT07739719)
- Testing
- LAIV FLUMIST
- Where
- Canada
- Volunteers
- 966 people, healthy volunteers welcome
- Sponsor
- McMaster University
Healthy
Infectivity of Norovirus in Shellfish Treated With High Hydrostatic Pressure Processing-Human Challenge Study
Norwalk virus and related "Norwalk-like viruses" are the most common cause of outbreaks of stomach sickness (nausea, vomiting, diarrhea) in older children and adults in the United States.
- Trial name
- Shellfish (NCT00674336)
- Testing
- High Hydrostatic Pressure Processing
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Emory University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.